Long-Acting Injectable Cabotegravir Plus Rilpivirine Safe, Effective, Well-Tolerated At 124 Weeks In FLAIR Trial

Healio (10/22, Stulpin) reported trial data indicate “long-acting injectable cabotegravir plus rilpivirine effectively maintained viral suppression of HIV among adults with or without a 1-month oral lead-in phase.” According to the results of the “ongoing...